A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation by Babar Khawar et al.
EUROPEAN JOURNAL 
OF MEDICAL RESEARCH
Khawar et al. European Journal of Medical Research  (2015) 20:7 
DOI 10.1186/s40001-015-0083-yREVIEW Open AccessA panoramic spectrum of complex interplay
between the immune system and IL-32 during
pathogenesis of various systemic infections and
inflammation
Babar Khawar1, Muddasir Hassan Abbasi1,2 and Nadeem Sheikh1*Abstract
Cytokines have always been of great interest due to their vast potential and participation in the progression and
pathogenesis of various ailments. Interleukin-32 (IL-32) is a recently identified cytokine, whose gene is located on
human chromosome 16 p13.3, with eight exons and six splice variants (IL-32α to IL-32ζ). IL-32α, the most abundant
form, is secreted by different types of cells including T cells, natural killer (NK) cells, monocytes, endothelial cells and
epithelial cells. It acts as a preferential mediator and effector of abnormal immune responses to multiple inflammatory
and auto immune diseases including rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), inflammatory
bowel disease (IBD), etc. It was found to stimulate the induction of various chemokines, pro-inflammatory cytokines
including IL-1β, IL-6, IL-8, TNF-α and macrophage inflammatory protein-2 (MIP-2). Hence, IL-32 mediates the crucial
interplay among immune system and body cells during pathogenesis of various insults. The aim of the present
effort is to summarize the role, mechanism of pathogenesis and potential therapeutic applications of IL-32 in
different systemic infections and diseased conditions.
Keywords: Auto immune disease, Inflammatory bowel disease, Interleukin-32, Rheumatoid arthritisIntroduction
Cytokines are small, pleiotropic, nonstructural soluble
factors (probably polypeptides/proteins) with molecular
weights ranging between 8 to 40,000 Da. Every cell is
capable of producing cytokines and can respond to
them. Cytokines are principally involved in homeostatic
mechanisms by mediating and regulating inflammatory/
immune responses to various insults like diseased condi-
tions or infections and affect cellular interactions and cell
communication system. These peptides could be autocrine,
paracrine and perhaps even endocrine regarding their site
of action [1,2]. These are principally classified into various
classes on the basis of their biological roles. The term
cytokines includes lymphokines, monokines, chemokines
and interleukins made and secreted by a variety of immune
system components, specifically, lymphocytes, monocytes* Correspondence: s_nadeem77@yahoo.com
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unless otherwise stated.and leukocytes. The aim of the current review is to
emphasize the existing therapeutic potential and future
perspective of interleukin-32 (IL-32). The extraordinary
qualities of this interleukin have prompted their applica-
tion in the field of medical biology.
Interleukin-32 (IL-32), a recently described cytokine
(previously called natural killer cell transcript 4 (NK4)),
found originally as a transcript that is in a cDNA library
derived from IL-2 activated natural killer cells [3], as
well as being expressed selectively in T-lymphocytes,
monocytes and epithelial cell lines [4-6]. It is an important
player in innate and adaptive immune responses in vitro
[4], and its production is predominantly induced by IL-1β,
TNF-α, IL-2 or IFN-γ in blood monocytes and epithelial
cells [3,5,7]. IL-32 is a pleiotropic cytokine that is involved
in number of biological functions including cell differ-
entiation [8-10], stimulation of pro- or anti-inflammatory
cytokines [11-13] and cell death, especially apoptosis
(Figure 1) [14,15].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Production of IL-32 by various body cells, namely, epithelial cell lines, T-lymphocytes and monocytes, and its
involvement in different cellular processes including cell differentiation and cell death, as well as interactions with the
immune system.
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Human recombinant IL-32 does not exhibit similarities
with known cytokine families, yet several properties are
typical of a pro-inflammatory cytokine [5,16,17]. It was
discovered accidently while studying the genes induced
by IL-18 and was found to stimulate the production of
various chemokines, pro-inflammatory cytokines including
IL-1β, IL-6, IL-8, TNF-α and macrophage inflammatory
protein-2 (MIP-2) [5,10,17,18].
Inflammation or infection with various pathogens in-
cluding Mycobacterium tuberculosis, Epstein-Barr virus
(EBV), human immunodeficiency virus (HIV) and influ-
enza A virus have been reported to induce the expres-
sion of IL-32 [19-22]. The IL-32 gene is located on
human chromosome 16 p13.3, which is organized into
eight exons with six splice variants of the gene; these
variants have been described as IL-32α, IL-32β, IL-32γ,
IL-32δ, IL-32ε and IL-32ζ [23,24], of which, IL-32α is
the most abundant transcript [25].
Anti-tumor activity of NK cells is provoked by IL-12
and IL-18, both of which induce IL-32 production that
stimulates TNF-α synthesis enhancing NK apoptotic ac-
tivity [3,5,6,26]. IL-32 was found in cytosol as well as in
the nucleus. Park et al. [27] reported that IL-32 en-
hances the anti-tumor activity specifically for NK-92
cells upon introduction of the death receptor and the ac-
tivation of caspase-3 pathway in cancer cells.IL-32 has been reported to play a key role in the
pathogenesis of various disorders, including infectious
autoimmune and inflammatory diseases.IL-32 in rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune
disease that is often associated with inflammation and
joint destruction, which ultimately results in signifi-
cant disability. Cagnard et al. [28] reported an eleva-
tion in IL-32 expression in patients with rheumatoid
arthritis (RA) in contrast to osteoarthritis [28], and
the severity of the symptoms was found to be corre-
lated with high degree of expression of TNF-α, a
potent inducer of IL-32 mRNA expression in human
synovial fibroblasts. Overexpression of IL-32 in turn
stabilized the mRNA transcripts of other cytokines,
namely, those for TNF-α, IL-1β and IL-8.
In another study on anti-TNF-α treatment in pa-
tients with RA, synovial knee biopsies showed a signifi-
cant decrease in IL-32 expression [11]. Similarly,
human IL-32 leads to joint swelling and recruitment of
inflammatory cells, along with cartilage derangements,
when injected in joints of naïve mice. In contrast, in a
TNF-α deficient mice model, joint swelling and influx
of inflammatory cells have been drastically decreased
(Figure 2) [22].
Figure 2 Mechanism of pathogenesis of autoimmune disease,
rheumatoid arthritis (RA). In a classical pathway, pro-inflammatory
cytokines TNF-α induce expression of IL-32, which leads not only to
progression of disease but may cause injury.
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monocytes and synovial tissue were analyzed from
healthy volunteers and RA patients. The IL-32γ level
was found significantly upregulated in RA patients in
accordance with results of an experimental model of in-
flammatory arthritis in mice in which the administration
of IL-32 aggravated disease conditions [8,29,30]. Syner-
gism between the soluble receptor activator of nuclear fac-
tor κ-B ligand (sRANKL) and IL-32γ was demonstrated.
In IL-32γ treated cultures, the presence of sRANKL ag-
gravates the activity of osteoclasts, as well as increases the
resorption of tissues, compared to IL-17 [8]. Presence of
significantly high levels of IL-32 in synovial tissue biopsies
of RA as compared to its absence in osteoarthritic (OA)
patients confirmed that IL-32 is potent mediator of the
active osteoclastogenic activity [22]. This extraordinary
interleukin was also found to be involved in the release of
prostaglandin E2 from human blood monocytes and
mouse macrophages. IL-32 mediated cell influx and joint
swelling was found to be reduced in TNFα-deficient mice,
which suggest that the expression of this cytokine is
TNFα-dependent in RA [22]. The signal pathway of
TNFα-dependent mediation of IL-32 expression in RA
was explored by Moon et al. They reported the involve-
ment of spleen tyrosine kinase (Syk)/ protein kinase Cδ
(PKCδ)/c-Jun N-terminal kinase (JNK) pathways in the
regulation of IL-32 induction by TNF-α in synovial fi-
broblasts [29]. An upregulated level of IL-32 was found
in cases of RA fibroblast-like synoviocytes (FLS), while
it was absent in biopsies of OA. This increased level of
IL-32 was found to be suppressed by small interferingRNA (siRNA) of these enzymes as well as by the inhibitors
of PKCδ, Syk and JNK. Recent research has revealed the
key role of FLS in osteoclastic activity, as well as their role
in pannus formation in joints [31]. Various factors and in-
teractions such as cell-to-cell contacts, pathogen-associated
molecular patterns (PAMPs), pattern-recognition receptors
(PRRs), and cytokine environment, along with damage-
associated molecular patterns (DAMPs), may be involved
in the activation of FLS. Lipopolysaccharide (LPS), pep-
tidoglycan and some other bacterial products have also
been reported, which result in the activation of FLS activ-
ity by interacting with PRRs of these cells [32,33]. FLSs, in
response to inflammatory stimuli, expressed a large
number of PRRs, especially TLR2, TLR3 and TLR4,
[34,35]. FLS-induced inflammatory response is medi-
ated by synthesizing a variety of cytokines, prostanoids,
chemokines, and nitric oxide (NO) [31]. TNF-α, IFN-γ,
and PAMPS have been reported to regulate the secre-
tion of IL-6, IL-8, and B-cell-activating factor by FLS
[36,37]. IL-32 and IL-17 are two major inflammatory cyto-
kines, which together are thought to play a similar role
and synergistically involved in differentiation of osteo-
clasts. A few new genes that is, CXC chemokine receptor
4 (CXCR4), IL-32 and lamina propria lymphocytes (LPL)
were confirmed due to expression of IL-17A and IL-17 F
in combination with TNF-α in RA synoviocytes [38].
CD4+ T cells or dendritic cells and RA FLSs have been
previously employed in various studies to reveal a recip-
rocal interaction between IL-32 and TNF-α depicting a
TNF-α/IL-32/TNF-α-positive auto-inflammatory loop
[11]. Anti-TNF-α treatment of RA patients has resulted
in a significant reduction of IL-32 peptides in synovial
tissue [11]. Recently, IL-32 g was reported to be involved
in maturation and activation of immature dendritic cells
(DCs), along with an increased Th1 and Th17 response by
IL-12 and IL-6 [39]. Both IL-17 and IL-32 influence
pathogenesis by TNF-R1 dependent/independent path-
way by employing p300 and death-associated protein
kinase 1 (DAPK-1) [40]. IL-32 and IL-17 can augment
osteoclastogenesis by RANKL-dependent manner, as
well as reciprocally affect each other's production in RA
synovium.
IL-32β, δ, and γ mRNA overexpression in RA FLS is pri-
marily induced by TNF-α, IFN-γ and toll-like receptor
(TLR)-2, −3, and −4 ligands [41]. Mature IL-32 is expressed
by various cells of the body due to intracellular polyriboino-
sinic polyribocytidylic acid (poly I:C) and TNF-α.
The overexpression of IL-32 in a number of diseases
including asthma, inflammatory bowel disease (IBD) and
RA has been reported to be induced by IL-18 [5].
IL-32 in inflammatory bowel disease
Inflammatory bowel disease (IBD), a chronic and degener-
ating inflammatory disorder of the gastrointestinal tract
Figure 3 Mechanism of pathogenesis of inflammatory bowel
disease (IBD). IBD pathogenesis is initiated by bacterial peptidoglycan,
which induces caspase-1-dependent mechanism by NOD1 and NOD2,
which enhanced the expression of IL-32. IL-32 initiates the NF-κB
activation and a spectrum of various other inflammatory cytokines,
and this activation ultimately result in IBD.
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Crohn's disease (CD). The pathogenesis of disease has
been found to be associated with following common
symptoms: mild fever, abdominal pain, chronic diarrhea,
and ulceration of colon/ rectum often resulting in rectal
bleeding. In the case of CD, stenosis, fistulation, and
abscesses may be sometimes associated with former
symptoms, while in case of UC an additional problem
megacolon has been reported. Currently, the exact
mechanism involved in IBD is mysterious currently but
role of unidentified components of gut microflora has
been an established view in an abnormal cascade of
inflammatory responses during this disease [42-46].
Netea et al. [17] found that a bacterial peptidoglycan
(muramyl dipeptide) induced the expression of IL-32
with the nucleotide-binding oligomerization domain-
containing protein 1 (NOD1) and the nucleotide-binding
oligomerization domain-containing protein 2 (NOD2)
through a caspase-1-dependent mechanism that ultim-
ately induces activation of the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) and
augments the production of IL-1β and IL-6 [17,47]. Re-
cently, Crohn’s disease (CD) patients have been found to
have an enhanced IL-1β and NF-κB activity due to muta-
tion in NOD2. All of the above findings confirmed a key
role of IL-32 in the progression and pathophysiology of
IBD, especially in CD [48,49]. IL-32 and TNF-α seems
to play a role in the pathogenesis of IBD, as IL-32 is
found to be overexpressed in an amplified manner along
with TNF-α (Figure 3) [25].
A new isoform of IL-32 has been identified in human
colonic subepithelial myofibroblasts (SEMFs); this iso-
form lacks exon 3 and 4 of the IL-32γ isoform (longest
isoform) and was named as IL-32ε [50]. An enhanced
level of the transcript of IL-32ε was found in inflamed
mucosa of IBD patients. TNF-α, in a time- and dose-
dependent manner, was found to be an active inducer of
transcript of this new IL-32ε [50]. It has been reported
previously in a study in HT-29 cells, that transfection of
IL-32ε results in an overall decrease of IL-8 transcript
mediated by TNFα, but the expression of the shortest
isoform IL-32α, which lacks exon 3 and 7, showed no
effect on the IL-8 transcript. In vivo experiments were
inspected to find out the role of IL-32 in intestinal inflam-
mation by using an IL-32γ transgenic mouse (IL-32γ-TG)
that expressed human IL-32γ. Considerable amounts of
TNF-α were reported in the sera and colonic tissue of
IL-32γ-TG mice while the mice remain healthy. Because
of this enhanced pro-inflammatory cytokine, IL-32γ-TG
exhibited a slightly early and greater acute inflammation
as compared to wild type mice upon the dextran sodium
sulfate (DSS)-induced colitis. Nevertheless, there is a lesser
amount of colonic inflammation and better survival rate
compared with wild-type mice after day 6. The coloniclevel of inflammatory cytokine related to attenuated tissue
damage was significantly decreased in IL-32γ-TG-treated
with DSS and the constitutive level of IL-32γ in colonic
tissue was also decreased [51]. So conclusions can be
drawn on how IL-32γ enhances the innate inflammation,
as well as how it protects intestinal integrity.
IL-32 not only stimulates the production of various
inflammatory cytokines with monocytes but also causes
monocytes to differentiate into macrophage or dendritic
cells (DCs) [10]. IL-32 stimulates neutrophils directly to
produces IL-6 and IL-8 [8,51,52]. These differentiated
macrophages and DCs are potent source of some very
crucial inflammatory cytokines, that is, TNF-α, IL-1β,
and IL-6, which recruit T-cells in the inflamed area in
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proliferation of these T-cells to protect the host against
the invading pathogens. This increase in the numbers of
various immune cells without proper immune suppres-
sor molecules leads to infiltration of neutrophils in an
inflamed area, which results in the release of a variety of
neutrophil proteinases such as cathepsin G, elastase, and
proteinase 3 (PR3). These enzymes of serine proteinase
family are powerful mediators of mucosal tissue injury
exacerbating inflammation in CD and IBD. Though ex-
pression of IL-32 is elevated in the epithelial cells of
inflamed mucosa from IBD and CD patients the biological
role of IL-32 in vivo and in vitro was inconsistent. Eight
different IL-32 mRNA transcripts give rise to five IL-32
isoforms (Kim S, 2014 unpublished data). The diver-
gence of in vitro and in vivo data could be because of
the fact that each researcher has studied a different
IL-32 isoform.
In one study, the level of mRNA transcript and IL-32α
protein was found to be significantly high in the IBD
patients with inflamed epithelial mucosa compared to
normal individuals [48]. Further studies suggested that
IL-32 interacts with various other cytokines including
IL-1β, TNF-α and IFNγ and plays an important role in
pathophysiology of IBD and CD [53-55]. There is a
need of further studies to evaluate the precise role of
IL-32 in IBD and CD.
IL-32 in chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is cur-
rently one of the leading causes of morbidity and mor-
tality globally. COPD is a progressive disease occurring
as an inflammatory response to toxic particles or gases
[56], and careful estimates predict that it will be the
third major cause of death by the year 2020. COPD
lessens the quality of life, causes frequent hospital ad-
missions, and ultimately enhances the risk of death
[57-59]. In the US alone, the annual costs of COPD are
approximately $50 billion, and most of these costs are
due to exacerbations requiring hospitalization. The eti-
ology of COPD points toward the interactions between
genetic factors and various environmental factors, pre-
dominantly cigarette smoking [60]. More than 90% of
cases of COPD currently are due to chronic cigarette
smoking in westernized countries, which sets off an in-
flammatory response in peripheral lung tissues as well
as in the larger bronchi. But a number of recent studies
have reported a significant prevalence of COPD among
non-smokers and those who have never smoked. Various
studies have reported the persistence of chronic inflam-
mation throughout the airways, pulmonary vasculature,
lung parenchyma, and even outside the lungs [61,62]. A
variety of factors, including the environmental indoor
pollution because of use of biomass fuel consumptionand coal, may be important causes of it [56,63,64]. COPD
is characterized by constriction and obstruction of air pas-
sage ways and continual inflammation in pulmonary par-
enchymal tissues [57,65,66]. This inflammatory process is
much pronounced and persistent even after quitting
smoking in those susceptible smokers who develop
COPD. The pathogenic mechanisms of this inflamma-
tion are not fully understood yet but various researchers
have reported macrophages, T cells, and neutrophils as
being important players [18,66-72]. The major inflamma-
tory mediators in the progression of COPD were found to
be respiratory epithelial cells. Multiple factors including
smoking, infection and proteases have been reported by
numerous researchers to be involved in the activation of
airway epithelial cells in COPD [66,73-75]. These activated
cells secrete a vast array of molecules prominently growth
factors (GM-CSF and TGF-β), inflammatory cytokines
(TNF-α, some members of IL-7 family and IL-12) and
chemokines (CCL2, CXCL5, and CXCL10) [65,76,77].
Interferon gamma (IFN-γ) induces IL-32 expression in
monocytes and epithelial cells, which through the activa-
tion of two key pathways, namely, NF-κB and p38 MAPK,
results in the induction of an array of other proinflamma-
tory cytokines and chemokines, including TNF-α, IL-8
and MIP-2 [5], which are involved in the disease progres-
sion in COPD patients. Calabrese et al. [78] were the first
to report the effect of IL-32 in COPD-affected smokers.
For this purpose, smokers with COPD were compared
with non-COPD smokers and nonsmokers. The expres-
sion of IL-32 in lung tissue of COPD patients was found
to be increased and correlated with the degree of airflow
obstruction in vivo. IL-32/ TNF-α was suggested to play a
key role in the progression of the immune response in
COPD inflammation. Marked increased in IL-32 expres-
sion clearly showed role of IL-32 in the enhancement of
the immune response in COPD, with a possible impact on
disease progression . Kudo et al. [79] reported an increase
in the expression of IL-32 due to oxidative stress (H2O2)
and inflammation in human bronchial epithelial cells. A
significant increase in IL-32 expression in lung samples
and plasma of a similar cohort of COPD patients has been
reported [78,80].
Conclusions
Recently, the complex crosstalk between the immune
system and IL-32 has become a topic of hot debate.
From above data, it could be concluded that IL-32 is a
key player, which exerts its biological functions intracellu-
larly, inducing the expression of various pro-inflammatory
cytokines and, hence, contributing to the progression and
pathogenesis of various diseased conditions and systemic
infections. Despite the recent progress, a lot of hidden
potentials and features of this mysterious cytokine remain
to be revealed. Currently, it is a challenge to understand
Khawar et al. European Journal of Medical Research  (2015) 20:7 Page 6 of 8the balance between its beneficial and pathological roles
after administration or inhibition of this critical cytokine.
However, the current status of research indicates a wide
therapeutic potential of IL-32 in the medical area, in the
near future.
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